Electrocardiographic Markers of Sudden Cardiac Death Risk in End-Stage Renal Disease
Sudden cardiac death (SCD) is a major cause of mortality in people with end-stage renal disease (ESRD), particularly among patients receiving maintenance hemodialysis. The mechanisms are diverse: ventricular tachyarrhythmia, bradyarrhythmia, conduction disease, myocardial fibrosis, left ventricular hypertrophy, ischemia, autonomic dysfunction, and rapid changes in potassium or calcium during dialysis may all contribute. This complexity makes risk assessment more demanding than simply identifying a single abnormal electrocardiogram (ECG).
The surface ECG remains attractive because it is inexpensive, widely available, repeatable, and capable of capturing several components of arrhythmic vulnerability. Measures of ventricular repolarization, depolarization, conduction, and rhythm stability may provide clinically relevant signals. However, their interpretation in ESRD requires attention to dialysis timing, electrolyte status, medication exposure, heart rate, comorbid cardiovascular disease, and technical measurement quality.
Electrocardiographic markers of sudden cardiac death risk in end-stage renal disease should therefore be viewed as pieces of a broader risk profile. They can help identify changing electrical instability, guide closer surveillance, and support research into personalized prevention, but they do not independently determine who should receive an implantable cardioverter-defibrillator or other intervention.
Why Arrhythmic Risk Is Electrically Complex
Patients with ESRD often develop uremic cardiomyopathy, characterized by left ventricular hypertrophy, chamber remodeling, interstitial fibrosis, and impaired systolic or diastolic function. These structural changes create areas of conduction slowing and electrical heterogeneity. Coronary artery disease and prior infarction can add scar-related reentry, while diabetes and longstanding hypertension further amplify myocardial injury.
The dialysis procedure introduces a second layer of variability. Rapid removal of potassium, shifts in calcium and magnesium, changes in acid-base balance, and fluctuations in circulating volume can alter action potential duration and conduction. A patient’s ECG before dialysis may therefore differ meaningfully from the tracing recorded immediately after treatment. Symptoms, blood pressure, ultrafiltration volume, and laboratory results should be documented alongside every clinically important ECG.
Autonomic imbalance is also relevant. Reduced heart-rate variability, impaired baroreflex function, and heightened sympathetic activity may lower the threshold for ventricular arrhythmia. This helps explain why SCD events can cluster during or shortly after dialysis, although risk is influenced by the patient’s underlying disease and the dialysis prescription rather than by treatment timing alone.
QT Interval And Repolarization Heterogeneity
The corrected QT interval (QTc) is among the most studied ECG markers in renal disease. A prolonged QTc may indicate delayed ventricular repolarization and increased susceptibility to early afterdepolarizations and torsades de pointes. In ESRD, QT prolongation can reflect hypocalcemia, hypokalemia, hypomagnesemia, medications, autonomic dysfunction, myocardial hypertrophy, or uremic effects on ion channels.
QT correction formulas introduce important limitations. Bazett’s formula tends to overcorrect at fast heart rates and undercorrect at slow rates, both of which may occur in dialysis populations. Fridericia or Framingham corrections may provide more stable estimates, but consistent use of one method is essential when comparing serial measurements. Manual verification is advisable when T-wave morphology is abnormal, the T wave merges with the U wave, or automated software produces implausible values.
QT dispersion, defined as the difference between the longest and shortest QT intervals across ECG leads, has been proposed as a marker of spatial repolarization heterogeneity. Similarly, the interval from the peak to the end of the T wave (Tp-e), and the Tp-e/QT or Tp-e/QTc ratio, may reflect transmural dispersion of repolarization. These indices are biologically appealing, but they are vulnerable to lead selection, T-wave shape, heart rate, and measurement disagreement. Their prognostic value in ESRD remains less established than their association with electrical instability in selected studies.
Depolarization, Conduction, And Structural Clues
QRS duration reflects intraventricular conduction and may increase with bundle-branch block, ventricular hypertrophy, myocardial fibrosis, ischemic scar, or diffuse conduction system disease. A markedly prolonged QRS can identify patients with advanced electrical remodeling, although it is not specific for ventricular fibrillation risk. The presence of a wide QRS should prompt assessment of ventricular function, symptoms, medication effects, and potential indications for cardiac resynchronization rather than serving as an isolated SCD predictor.
Fragmented QRS, seen as additional R waves, notching, or multiple R-prime patterns in contiguous leads, may represent heterogeneous conduction through scarred or fibrotic myocardium. In patients with renal disease, it can accompany left ventricular hypertrophy, coronary disease, or uremic myocardial remodeling. Its interpretation is strongest when the finding is persistent, anatomically coherent, and supported by echocardiographic or cardiac magnetic resonance evidence.
Voltage criteria for left ventricular hypertrophy can be informative but are imperfect. Increased ventricular mass may raise arrhythmic risk, while obesity, edema, pericardial fluid, lung disease, and dialysis-related volume changes can reduce or distort ECG voltage. ST-T strain patterns, left atrial abnormality, pathological Q waves, and bundle-branch block add clinical context. A normal voltage tracing does not exclude substantial hypertrophy or fibrosis in ESRD.
Timing, Electrolytes, And Serial ECG Assessment
A single ECG provides a snapshot, whereas renal patients often experience rapid biological changes. For meaningful comparison, clinicians should record whether the tracing was obtained before dialysis, during treatment, or after treatment, together with recent potassium, calcium, magnesium, bicarbonate, and heart rate. The interval from the last dialysis session and the amount of ultrafiltration may also help explain new changes.
| ECG marker | Potential signal | Common confounders in ESRD | Practical interpretation |
|---|---|---|---|
| QTc prolongation | Delayed repolarization and possible torsades susceptibility | Electrolyte shifts, drugs, heart rate, correction formula | Confirm manually and repeat after reversible causes are addressed |
| QT dispersion | Spatial repolarization heterogeneity | Lead selection, T-wave morphology, measurement variability | Use cautiously; stronger as a research or longitudinal measure |
| Tp-e or Tp-e/QTc | Transmural repolarization dispersion | Poor T-wave definition, rate dependence, bundle-branch block | Interpret with the full ECG and clinical context |
| QRS widening | Delayed ventricular conduction or structural disease | Bundle-branch block, pacing, scar, hyperkalemia | Assess ventricular function and conduction-system disease |
| Fragmented QRS | Possible myocardial scar or fibrosis | Lead placement, LV hypertrophy, prior infarction | Seek corroboration from imaging and clinical history |
| ST-T abnormalities | Strain, ischemia, or repolarization disturbance | LVH, electrolyte abnormalities, digoxin, baseline disease | Compare with prior ECGs and symptoms |
Serial analysis can be more useful than a single threshold. A new QTc increase, emerging QRS widening, or transition from a stable to fragmented QRS pattern may signal changing myocardial conditions. Yet apparent changes can result from lead placement or differing heart rates, so repeat acquisition under comparable conditions is important.
Hyperkalemia deserves particular attention because its ECG manifestations can evolve from peaked T waves to PR prolongation, QRS widening, sine-wave morphology, and malignant ventricular rhythms. A deceptively normal ECG does not exclude dangerous hyperkalemia. Conversely, QT prolongation is more commonly associated with low calcium, low magnesium, certain drugs, or rapid electrolyte shifts than with isolated hyperkalemia. ECG interpretation must never delay urgent laboratory testing and treatment when severe electrolyte disturbance is suspected.
Combining ECG Findings With Clinical Risk
ECG markers become more informative when integrated with left ventricular ejection fraction, echocardiographic hypertrophy, cardiac magnetic resonance evidence of fibrosis, ischemic history, diabetes, peripheral vascular disease, prior syncope, documented nonsustained ventricular tachycardia, and medication exposure. The dialysis prescription also matters, including dialysate potassium and calcium concentrations, ultrafiltration rate, treatment duration, and adherence to prescribed sessions.
Medication review should include QT-prolonging antiarrhythmics, antibiotics, antidepressants, antipsychotics, antiemetics, and other agents whose effects may be amplified by impaired renal clearance. Beta-blockers and other rate-modifying drugs can alter QT correction and mask tachyarrhythmia symptoms. A careful review can uncover reversible risk before escalation to invasive testing or device-based therapy.
No ECG marker has sufficient specificity to replace clinical judgment. Primary-prevention defibrillator decisions in ESRD are complicated by competing mortality, infection risk, vascular access considerations, frailty, left ventricular function, and the uncertain transferability of evidence from general heart-failure populations. Electrophysiology consultation is particularly appropriate when there is unexplained syncope, sustained ventricular arrhythmia, marked conduction disease, or recurrent unexplained QT prolongation. Clinicians following developments in this area can consult the journal’s special issue collection for focused research and expert perspectives.
A Practical Framework For Clinical Use
A disciplined workflow improves the reliability of ECG-based risk assessment:
- Obtain a high-quality 12-lead ECG with consistent lead placement and document its relationship to dialysis.
- Measure QT and QTc carefully, using a consistent correction formula and manual review when T-wave morphology is unclear.
- Examine QRS duration, bundle-branch block, fragmented QRS, pathological Q waves, voltage, and ST-T abnormalities.
- Pair ECG findings with potassium, calcium, magnesium, medication review, symptoms, ventricular function, and prior tracings.
- Repeat the ECG after correcting reversible factors and refer promptly when syncope, sustained arrhythmia, severe conduction disease, or major dynamic changes are present.
The greatest value may come from tracking trends in an individual patient rather than applying rigid population cutoffs. A stable, modestly prolonged QTc may have a different meaning from a rapidly increasing QTc after medication changes or dialysis prescription adjustments. Likewise, a new wide QRS in a patient with hypotension or hyperkalemia demands a different response from a longstanding bundle-branch block with stable clinical status.
Research should continue to standardize ECG acquisition, define dialysis-specific reference ranges, and test whether combinations of ECG markers improve prediction beyond established clinical variables. Wearable monitoring, implantable device diagnostics, autonomic measures, and artificial intelligence may eventually complement the resting ECG, but each approach requires validation in diverse renal populations and careful attention to false-positive findings.
Clinicians, researchers, and trainees can follow emerging evidence, clinical guidance, and electrophysiology scholarship through the Journal of Arrhythmia. Applying these markers thoughtfully—while correcting reversible triggers and respecting the limits of prediction—can strengthen surveillance for ventricular instability and support more individualized care for people living with ESRD.